DaVita (DVA) Aperçu de l'action
DaVita Inc. fournit des services de dialyse rénale aux patients souffrant d'insuffisance rénale chronique aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 2/6 |
| Performances passées | 1/6 |
| Santé financière | 2/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
DVA Community Fair Values
Create NarrativeSee what 45 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
DaVita Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$232.08 |
| Plus haut sur 52 semaines | US$239.64 |
| Plus bas sur 52 semaines | US$101.00 |
| Bêta | 0.88 |
| Variation sur 1 mois | 10.68% |
| Variation sur 3 mois | 49.70% |
| Variation sur 1 an | 53.37% |
| Variation sur 3 ans | 129.33% |
| Variation sur 5 ans | 95.29% |
| Évolution depuis l'introduction en bourse | 5,595.20% |
Nouvelles et mises à jour récentes
Seeking Alpha • Jul 15
DaVita: I Believe This Is Overvalued
Summary DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share. I reiterate a Hold rating on DVA given limited risk/reward upside at current multiples and persistent volatility. Read the full article on Seeking Alpha
Mise à jour du récit • Jul 15
DVA: AI Kidney Care Platform Will Drive Future Earnings Repricing
Analysts have lifted the DaVita fair value estimate from $179.66 to $270.00, citing a series of higher price targets up to $270 and research that highlights sector tailwinds, ongoing growth investments, and company specific initiatives around advanced dialysis technologies, GLP-1 use, and home care services. Analyst Commentary Recent research updates around DaVita point to a more constructive tone, with several bullish analysts revising their fair value views higher and emphasizing the potential impact of company execution on advanced dialysis technologies, GLP-1 integration, and home care efforts.
Mise à jour du récit • Jun 30
DVA: Future Margin Assumptions And GLP-1 Headwinds May Restrain Upside
DaVita's updated analyst price target has shifted to $145 from $126, reflecting analysts' revised assumptions for lower discount rates, different revenue growth expectations, higher profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on DaVita points to a mixed set of views, with some analysts revising price targets and ratings based on updated assumptions around discount rates, revenue growth, margins, and valuation multiples.Recent updates
Seeking Alpha • Jul 15
DaVita: I Believe This Is Overvalued
Summary DaVita Inc. has more than doubled in share price within six months, driven by a strong Q1 '26 beat and a favorable court ruling. DVA fundamentals and long-term prospects remain largely unchanged, with 2026E AEPS recovery now expected at 30%+ and 10–16% annualized growth through 2028. I sold over 95% of my DVA position as the valuation exceeded $210/share, far above my fair value target of $130/share. I reiterate a Hold rating on DVA given limited risk/reward upside at current multiples and persistent volatility. Read the full article on Seeking AlphaMise à jour du récit • Jul 15
DVA: AI Kidney Care Platform Will Drive Future Earnings Repricing
Analysts have lifted the DaVita fair value estimate from $179.66 to $270.00, citing a series of higher price targets up to $270 and research that highlights sector tailwinds, ongoing growth investments, and company specific initiatives around advanced dialysis technologies, GLP-1 use, and home care services. Analyst Commentary Recent research updates around DaVita point to a more constructive tone, with several bullish analysts revising their fair value views higher and emphasizing the potential impact of company execution on advanced dialysis technologies, GLP-1 integration, and home care efforts.Mise à jour du récit • Jun 30
DVA: Future Margin Assumptions And GLP-1 Headwinds May Restrain Upside
DaVita's updated analyst price target has shifted to $145 from $126, reflecting analysts' revised assumptions for lower discount rates, different revenue growth expectations, higher profit margins, and a lower future P/E multiple. Analyst Commentary Recent Street research on DaVita points to a mixed set of views, with some analysts revising price targets and ratings based on updated assumptions around discount rates, revenue growth, margins, and valuation multiples.
Mise à jour du récit • Jun 16
DVA: Share Repurchases And GLP-1 Risks Will Shape Future Stock Economics
DaVita's analyst price target has been raised by $57, with analysts citing updated assumptions around discount rates, long term revenue growth, profit margin, and future P/E as key drivers of the revised valuation view. Analyst Commentary Recent research on DaVita highlights a cluster of upward price target revisions and an upgrade, with analysts revisiting their assumptions on discount rates, long term revenue growth, profit margins, and future P/E multiples.Mise à jour du récit • Jun 02
DVA: Share Repurchases And GLP-1 Headwinds Will Shape Future Kidney Care Economics
DaVita’s updated analyst price target holds steady at $193.71, with recent upward revisions from firms like TD Cowen, Truist, Barclays and an upgrade at Deutsche Bank. These moves reflect analysts’ focus on its refined discount rate, revenue growth outlook, profit margin assumptions and expected future P/E multiple.Mise à jour du récit • May 13
DVA: Buybacks And Revised Earnings Assumptions Will Confront Emerging GLP-1 Headwinds
DaVita's analyst price target has shifted from $151.71 to $193.71, with analysts pointing to updated assumptions for revenue growth, profit margins and future P/E multiples, along with a series of recent target hikes and an upgrade from major firms as key drivers behind the change. Analyst Commentary Recent Street research on DaVita has been active, with several firms revisiting their models and adjusting targets.Mise à jour du récit • Apr 28
DVA: Buybacks And Earnings Assumptions Will Shape Future Return Balance
Analysts have raised DaVita's consolidated price target by $30 to $151.71, citing updated views on the discount rate, revenue growth, profit margin and future P/E assumptions. Analyst Commentary Recent Street research on DaVita has centered on higher price targets and refreshed assumptions around discount rates, revenue outlook, margins and future P/E multiples.Mise à jour du récit • Apr 07
DVA: Buyback Pace And Long Term Earnings Assumptions Will Shape Future Returns
Analysts raised their DaVita price targets by up to $30, citing updated assumptions for discount rates and long term earnings multiples, while keeping core fair value drivers broadly unchanged. Analyst Commentary Recent research updates around DaVita have focused on recalibrating valuation frameworks rather than shifting the core business thesis.Mise à jour du récit • Mar 23
DVA: Ongoing Buybacks And Revised P/E Assumptions Will Shape Future Returns
DaVita’s analyst price target has been revised to $151.71, with analysts pointing to updated assumptions around the discount rate and forward P/E as key drivers of the refreshed outlook. Analyst Commentary Recent Street research on DaVita points to a cluster of higher price targets, with several firms revisiting their models around discount rates and forward P/E assumptions.Mise à jour du récit • Mar 08
DVA: Ongoing Buybacks And Repriced Execution Risk Will Shape Future Returns
Our updated analyst price target for DaVita edges higher by a few dollars to reflect slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E, generally in line with the recent series of upward target revisions from Truist, TD Cowen, UBS and Barclays. Analyst Commentary Bullish Takeaways Bullish analysts raising price targets by US$4 to US$30 signal increased confidence in DaVita's ability to execute against current expectations rather than a complete reset of the story.Mise à jour du récit • Feb 21
DVA: Buybacks And Richer P/E Assumptions Will Shape Future Return Potential
Analysts have raised their DaVita fair value estimate from $147.75 to $151.71, reflecting updated assumptions on the discount rate, revenue growth, profit margins, and future P/E following a series of recent price target increases from major research firms. Analyst Commentary Recent price target changes from several firms point to a reappraisal of DaVita's risk and reward profile, which feeds directly into the updated fair value estimate.Article d’analyse • Feb 06
Even With A 30% Surge, Cautious Investors Are Not Rewarding DaVita Inc.'s (NYSE:DVA) Performance Completely
DaVita Inc. ( NYSE:DVA ) shares have had a really impressive month, gaining 30% after a shaky period beforehand. Not...Mise à jour du récit • Feb 05
DVA: Updated Cash Returns And Margin Assumptions Will Shape Future Upside Potential
Our DaVita view now reflects a higher fair value estimate of $147.75, up from $143.00. Analysts point to updated assumptions on discount rate, revenue growth, margin profile, and a lower future P/E as key drivers behind the price target revisions across recent Street reports.Mise à jour du récit • Jan 22
DVA: Share Repurchases And Kidney Research Pipeline Will Support Future Upside
Analysts have kept their fair value estimate for DaVita steady at US$143.00. They cited only small model tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major shift in their outlook.Mise à jour du récit • Jan 07
DVA: Clinical Research Pipeline And Buybacks Will Support Earnings Despite Reimbursement Headwinds
Analysts have trimmed their price target for DaVita by about $1.50 to $143, reflecting slightly higher discount rate and P/E assumptions while keeping growth and margin expectations broadly in line. What's in the News DaVita plans to unveil six new studies at the American Society of Nephrology's Kidney Week 2025 in Houston, focused on dialysis treatments, middle molecule clearance, access to transplantation and end of life care (Key Developments).Mise à jour du récit • Dec 20
DVA: Clinical Initiatives And Buybacks Will Support Earnings Despite Reimbursement Headwinds
Analysts modestly raised their price target on DaVita to about $145 per share, reflecting slightly lower discount rate assumptions and a marginally improved long term earnings outlook, while maintaining stable fair value and growth expectations. What's in the News DaVita will unveil six new clinical studies at ASN Kidney Week 2025 in Houston, including an oral presentation on GLP-1 receptor agonist use and its association with lower hospitalization rates in end stage kidney disease patients (company announcement).Mise à jour du récit • Dec 06
DVA: Hospital Fundamentals Will Support Earnings Amid Tougher Reimbursement Outlook
Analysts have modestly reduced their price target on DaVita to $140 from $145, reflecting increased concern about a more challenging policy and reimbursement environment, despite generally solid hospital fundamentals. Analyst Commentary Analyst sentiment around DaVita remains mixed, with modestly reduced price targets reflecting both confidence in the company’s operational footing and caution about the evolving reimbursement backdrop.Mise à jour du récit • Nov 22
DVA: Hospital Fundamentals And Resilient Execution Will Drive Steady Performance
DaVita’s analyst price target has been revised downward from $147.13 to $144.50, as analysts cite a cautious outlook due to anticipated policy and reimbursement challenges, despite otherwise steady hospital fundamentals. Analyst Commentary Analysts have offered a range of perspectives on DaVita following the recent adjustment to its price target.Mise à jour du récit • Nov 03
DVA: Policy Shifts And Operational Recovery Will Shape Outlook In 2025
DaVita's analyst price target has been reduced from $150.50 to $147.13, as analysts cite ongoing concerns over policy headwinds and recent operational challenges that are impacting forecasts. Analyst Commentary Analysts have updated their outlook on DaVita based on recent sector-wide developments and company-specific events.Mise à jour du récit • Oct 20
Aging Population And AI Will Reshape Dialysis Care
DaVita's analyst price target has been revised downward from $153.50 to $150.50. This change reflects ongoing concerns among analysts about reimbursement challenges and the impact of recent operational disruptions.Mise à jour du récit • Sep 04
Aging Population And AI Will Reshape Dialysis Care
Analysts have revised their outlook on DaVita to reflect lower treatment growth, reduced revenue per treatment, and ongoing operational challenges stemming from cyberattack disruptions, resulting in a consensus price target that remains unchanged at $153.50. Analyst Commentary Bearish analysts revised down treatment growth expectations due to higher missed treatment rates stemming from cyberattack disruptions.Article d’analyse • Aug 05
Investors Aren't Entirely Convinced By DaVita Inc.'s (NYSE:DVA) Earnings
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Seeking Alpha • Mar 17
The DaVita Dilemma: Flat Patient Enrollment And Lawsuits, Yet An Improvement In Net Income Margin
Summary Between 2016 and 2024, DaVita's revenues grew less proportionally than the U.S. inflation. DVA has experienced difficulty enrolling more patients in its dialysis program, reporting a decline in its patients since 2019. Since 2012, the company has experienced lawsuits, which have cost approximately $1,000 million in payments and have negatively affected its reputation. The net income of DaVita increased by 50.59% between 2017 and 2024. In the last year, the company reported an 11.66% net income margin. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
DaVita: Momentum Could Fade Given High Valuation
Summary DaVita has returned ~60% over the last year, backed by superior earnings growth; however, going forward, I believe earnings growth should slow down. The Company faces headwinds from supply chain issues, higher mortality rates, and increased interest expenses, but tailwinds from lower center closure costs and Latin America acquisitions should more than offset headwinds. DVA stock is currently trading at a premium compared to the historical average. Applying a 14x PE multiple to the 2025 consensus EPS of $11.44, I estimate a fair value of $160 per share, below the current $177. Read the full article on Seeking AlphaSeeking Alpha • Nov 14
DaVita: Better Results Than Fresenius, But A 'Hold' Due To Valuation
Summary Despite operational success and growth potential, I rate DaVita Inc. a “Hold” due to its high debt, lack of dividend, and current overvaluation. DaVita excels in dialysis services but faces significant risks from debt servicing costs, macroeconomic factors, and potential policy changes. The company's recent financial performance, including a decline in net income and increased debt costs, underscores my conservative valuation approach. I assign DaVita a price target of $130/share, reflecting a cautious outlook on growth and valuation amidst industry and economic uncertainties. Read the full article on Seeking Alpha
Nouveau récit • Aug 22
Critical Investments And Policy Changes Propel Healthcare Innovator Towards Brighter Financial Horizons
DaVita's investments in technology and workforce initiatives aim to enhance revenue operations and patient care, contributing to future growth and profitability.Rendement pour les actionnaires
| DVA | US Healthcare | US Marché | |
|---|---|---|---|
| 7D | 0.2% | 0.7% | -0.7% |
| 1Y | 53.4% | 40.6% | 17.3% |
Rendement vs Industrie: DVA a dépassé le secteur US Healthcare qui a rapporté 40.6 % au cours de l'année écoulée.
Rendement vs marché: DVA a dépassé le marché US qui a rapporté 17.3 % au cours de l'année écoulée.
Volatilité des prix
| DVA volatility | |
|---|---|
| DVA Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: DVA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de DVA ( 7% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1994 | 78,000 | Javier Rodriguez | www.davita.com |
DaVita Inc. fournit des services de dialyse rénale aux patients souffrant d'insuffisance rénale chronique aux États-Unis. L'entreprise exploite des centres de dialyse rénale et fournit des services de laboratoire connexes dans les centres de dialyse ambulatoires. Elle propose également des services de dialyse ambulatoire, hospitalière et à domicile ; elle exploite des laboratoires cliniques qui fournissent des tests de laboratoire de routine pour la dialyse et d'autres tests de laboratoire prescrits par le médecin pour les patients souffrant d'insuffisance rénale chronique ; elle fournit également des services de gestion et d'administration aux centres de dialyse ambulatoire.
DaVita Inc. Résumé des fondamentaux
| DVA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$15.23b |
| Bénéfices(TTM) | US$756.42m |
| Recettes(TTM) | US$13.84b |
19.7x
Ratio P/E1.1x
Ratio P/SLe site DVA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| DVA compte de résultat (TTM) | |
|---|---|
| Recettes | US$13.84b |
| Coût des recettes | US$9.35b |
| Marge brute | US$4.49b |
| Autres dépenses | US$3.73b |
| Les revenus | US$756.42m |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Aug 04, 2026
| Résultat par action (EPS) | 11.78 |
| Marge brute | 32.45% |
| Marge bénéficiaire nette | 5.47% |
| Ratio dettes/capitaux propres | 996.9% |
Quelles ont été les performances à long terme de DVA?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/22 22:45 |
| Cours de l'action en fin de journée | 2026/07/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
DaVita Inc. est couverte par 28 analystes. 7 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Matthew Gillmor | Baird |
| Sarah James | Barclays |
| Andrew Mok | Barclays |